Credit Business Headwinds Persisting Through Q2
Paisabazaar acknowledged being on "the opposite side" of high approval rates from last year. Expects bottoming out with recovery only in Q3, creating continued drag on consolidated profitability.
PB Fintech · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Paisabazaar acknowledged being on "the opposite side" of high approval rates from last year. Expects bottoming out with recovery only in Q3, creating continued drag on consolidated profitability.
Analyst Suresh Ganapathy raised concern that at 25% market share in term and ~15% in Health with industry growth constrained to 15%, sustaining 30%+ growth becomes mathematically challenging. Management deflected by saying they are in "market creation" not "market share" game.
As Health vintage grows, renewal economics could deteriorate (Health renewal rates lower than term). Management acknowledged this but stated no change seen yet in renewal take rates at 6.9%.
Despite representing 80-85% of the insurance market, Policybazaar's savings share remains at ~2% (5% ex-LIC), flat for some time. Management cited product complexity and consumer education challenges, acknowledging it "takes time."
Fresh Health business operates at ~-20% EBITDA vs. 75-80% for renewal business. Rapid Health growth is creating margin headwind. Management explicitly stated Health growth "is not helping short-term profitability" but they will continue regardless.